Ampio rails against FDA ruling as stock crashes

9 August 2018
2019_biotech_test_vial_discovery_big

It was a black, black Wednesday for Ampio Pharmaceuticals (NYSE: AMPE) as its stock slumped to a value of just $0.61.

That represents a 79% decline in a day and in after-hours trading the value slipped by a further 26%, hinting at a tough day to come on Thursday too.

The reason for the investor desertion was that the US Food and Drug Administration (FDA) ruled that a further study was needed for the company’s treatment of osteoarthritis of the knee, to support a marketing application.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology